Toronto, Ontario--(Newsfile Corp. - May 17, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has completed a non-brokered private placement offering (the "Offering") of 50,000,000 units ("Units"), at a price of $0.015 per Unit, for total gross proceeds of $750,000.

Toronto, Ontario--(Newsfile Corp. - May 9, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company"), through its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), is excited to announce that it has filed pivotal patents for technology designed to facilitate maximum filter configuration flexibility when it comes to addressing varying water quality issues.

Toronto, Ontario--(Newsfile Corp. - April 22, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it plans to complete a non-brokered private placement offering (the "Offering") of up to 50,000,000 units ("Units"), at a price of $0.015 per Unit, for total gross proceeds of up to $750,000.

Toronto, Ontario--(Newsfile Corp. - April 12, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") and its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), are excited to share that on April 10, 2024, the Biden-Harris Administration in the United States has issued a groundbreaking and first-ever national, legally enforceable drinking water standard to protect communities from exposure to harmful per-and polyfluoroalkyl substances ("PFAS"), also known as "forever chemicals."

Toronto, Ontario--(Newsfile Corp. - March 4, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has entered into a market making services agreement (the "Agreement") with Independent Trading Group (ITG) Inc. ("ITG") to provide market making services in accordance with Canadian Securities Exchange (the "CSE") policies (the "Services"). ITG will trade shares of the Company on the CSE with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares.

VANCOUVER, BC, Dec. 18, 2023 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that, further to its press release dated October 23, 2023, it has completed the acquisition of all of the outstanding shares of Toppen Health Inc. ("Toppen"), a US-based innovative health and wellness company, dedicated to delivering state-of-the-art water filtration solutions (the "Acquisition").

Toronto, Ontario--(Newsfile Corp. - October 23, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that has entered into a definitive share purchase agreement dated October 10, 2023 (the "Purchase Agreement") with Toppen Health Inc. ("Toppen") and shareholders holding a majority of the issued and outstanding shares of Toppen (the "Toppen Shares"), a US-based innovative health and wellness company, dedicated to delivering state-of-the-art water filtration solutions (the "Proposed Acquisition"). The Company intends to enter into separate purchase agreements with the remaining Toppen shareholders prior to closing of the Proposed Acquisition.

VANCOUVER, BC, Oct. 19, 2023 /CNW/ - The following issues have been halted by CIRO:

Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated September 8, 2023, it has closed the second tranche of its previously-announced non-brokered private placement (the "Unit Offering") issuing 21,500,000 units ("Units"), at a price of $0.01 per Unit, for gross proceeds of $215,000. Including the first tranche of the Unit Offering, the Company has issued a total of 64,250,000 Units for total gross proceeds of $642,500.

Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it plans to complete a second tranche of its non-brokered private placement of units ("Units") to raise additional gross proceeds of up to $300,000.00 (the "Unit Offering") through the issuance of up to an additional 30,000,000 Units. The Units will be offered at a price of $0.01, with each Unit consisting of one common share ("Share") and one half of one common share purchase warrant ("Warrant"). Each full Warrant will be exercisable to acquire one Share ("Warrant Share") for a period of eighteen months following the closing of the Unit Offering at an exercise price of $0.10 per Warrant Share.

TORONTO, Aug. 14, 2023 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated July 4, 2023, it has closed its previously-announced non-brokered private placement (the "Unit Offering") of 42,750,000 units ("Units") at a price of $0.01 per Unit for gross proceeds of $427,500.

TORONTO, July 6, 2023 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company. The Company thanks Mrs. Mondin for her service as a director of the Company and wishes her all the best in her future endeavors.

VANCOUVER, BC, July 4, 2023 /CNW/ - Trading resumes in:

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE U.S./

VANCOUVER, BC, July 4, 2023 /CNW/ - The following issues have been halted by CIRO:

Toronto, Ontario--(Newsfile Corp. - November 7, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022, October 11, 2022 and October 31, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022 and October 11, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Toronto, Ontario--(Newsfile Corp. - October 11, 2022) -  Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022 and September 26, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Toronto, Ontario--(Newsfile Corp. - September 26, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press release of September 13, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that further to its press release on August 18, 2022, the British Columbia Securities Commission ("BCSC") has granted a management cease trade order (the "MCTO"), pursuant to the Company's application made under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The MCTO as issued is in connection with the delay by the Company in filing its audited annual financial statements (the "Annual Financial Statements"), management's discussion and analysis ("MD&A") and related certifications for the fiscal year ended April 30, 2022 (the "Filing Deadline") before the prescribed deadline of August 29, 2022. The issuance of a management cease trade order will not affect the ability of persons who have not been directors, officers or insiders of the Company to trade in their securities.

Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces today that the Company anticipates being late in filing its annual audited consolidated financial statements (the "Annual Financial Statements") and related annual management discussion and analysis ("MD&A") for the year ended April 30, 2022, by the prescribed deadline of August 29, 2022 (the "Filing Deadline") in accordance with the requirements of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102") and National Instrument 52-109 - Certification of Disclosure in Issuer's Annual and Interim Filings, as applicable.

Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic.

Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

TORONTO, Oct. 12, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 14, 2021 and September 28, 2021, the Company is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

TORONTO, Sept. 28, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press release dated September 14, 2021, the Company is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

TORONTO, Sept. 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

TORONTO, Aug. 31, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed deadline of August 30, 2021, and its interim financial statements (the "Interim Financial Statements") and related MD&A for the interim period ended July 31, 2021, by the prescribed deadline of September 29, 2021.

TORONTO, July 14, 2021 /PRNewswire/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, taking place July 15 - 16, 2021.

TORONTO, July 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, taking place July 15 - 16, 2021.

Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.

Detroit, Michigan--(Newsfile Corp. - June 2, 2021) - Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration.

LONDON and TORONTO, May 18, 2021 /CNW/ - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and ma

TORONTO, April 21, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

TORONTO, April 12, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") today announced that it has retained KCSA Strategic Communications ("KCSA"), a leading New York City-based communications firm.

TORONTO, March 11, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations.

VANCOUVER, BC, Feb. 23, 2021 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - February 23, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.

VANCOUVER, BC, Feb. 23, 2021 /CNW/ - The following issues have been halted by IIROC:

TORONTO, ON / ACCESSWIRE / February 22, 2021 - Plant-Based Investment Corp. ("PBIC", or the "Company") (CSE:PBIC), announces that the Company has acquired 3,333,333 units (the "Units") of Aion Therapeutic Inc. ("AION") (CSE:AION) at a price of $0.075 per Unit for a total subscription amount of approximately $250,000 through a non-brokered private placement (the "Offering"). Each Unit is comprised of one common share of AION ("Common Share") and one-half of

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 6,666,333 units ("Units") at a price of $0.075 per Unit for gross proceeds of approximately $499,975 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.

Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has granted and issued options for the purchase of up to 4,000,000 common shares of the Company to a number of the Company's officers, directors and consultants. The stock options were granted on February 2, 2021 in accordance with the Company's stock option plan and are exercisable for a period of three years from the date of issuance at an exercise price of $0.15 per common share.

Toronto, Ontario--(Newsfile Corp. - December 23, 2020) -  Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 15,384,615 units ("Units") at a price of $0.065 per Unit for gross proceeds of $1,000,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.

Toronto, Ontario--(Newsfile Corp. - October 30, 2020) -  Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible debenture dated December 10, 2017 in the principal amount of $237,500, in each case, issued by the Company in favour of the Lender (collectively, the "Convertible Debentures").

Neuroscientist, Healthcare Technology Entrepreneur to Lead Aion Through Important Next Phase

Toronto, Ontario--(Newsfile Corp. - September 18, 2020) -  Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 9,090,907 units ("Units") at a price of $0.055 per Unit for gross proceeds of approximately $500,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.

Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion Therapeutic

Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has filed five patent applications with the United States Patent and Trademark Office (USPTO) pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their medicinal properties. These patent applications have formulation claims directed to methods of treating numerous conditions including cancer, psychiatric disorders, addiction (opioid and alcohol), viral diseases, obesity, and inflammatory disorders. These first five patents are just the beginning of what the Company expects to be a full portfolio of intellectual property including blocking patents designed to protect Aion Therapeutic's discoveries.

Toronto, Ontario--(Newsfile Corp. - August 31, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion" or the "Company") is pleased to announce that Dr. Stephen D. Barnhill, Executive Chair of the Board, will present live during the Microdose "Psychedelic Capital Series" on Thursday, September 3, 2020 at 1:15 P.M. Eastern Time.

Toronto, Ontario--(Newsfile Corp. - Le 27 aout/August 2020) - Osoyoos Cannabis Inc. has announced a name and symbol change to Aion Therapeutic Inc. (AION).